Abstract
Recent years have seen extensive growth in the understanding of the role(s) of the various PKC isozymes and novel receptors for the phorbol ester tumor promoters. The PKC family of serine-threonine kinases is an important regulator of signaling cascades that control cell proliferation and death, and therefore represent targets for cancer therapy. While past interests have focused on PKC-selective inhibitors, more recently, intensive research has been underway for selective activators and inhibitors for each individual PKC isozyme. In the past few years a large number of PKC activators and inhibitors with potential as anticancer agents have been developed. A number of these compounds are already in Phase II clinical testing. As a new generation of cancer chemotherapeutic agents are designed, developed and put through a series of rigorous clinical trials, we can anticipate achieving exquisite control over PKCmediated regulatory pathways, leading ultimately to a greater understanding of different cancers.
Current Pharmaceutical Design
Title: Protein Kinase C Isozymes, Novel Phorbol Ester Receptors and Cancer Chemotherapy
Volume: 7 Issue: 17
Author(s): Orla P. Barry and Marcelo G. Kazanietz
Affiliation:
Abstract: Recent years have seen extensive growth in the understanding of the role(s) of the various PKC isozymes and novel receptors for the phorbol ester tumor promoters. The PKC family of serine-threonine kinases is an important regulator of signaling cascades that control cell proliferation and death, and therefore represent targets for cancer therapy. While past interests have focused on PKC-selective inhibitors, more recently, intensive research has been underway for selective activators and inhibitors for each individual PKC isozyme. In the past few years a large number of PKC activators and inhibitors with potential as anticancer agents have been developed. A number of these compounds are already in Phase II clinical testing. As a new generation of cancer chemotherapeutic agents are designed, developed and put through a series of rigorous clinical trials, we can anticipate achieving exquisite control over PKCmediated regulatory pathways, leading ultimately to a greater understanding of different cancers.
Export Options
About this article
Cite this article as:
Orla P. Barry and Marcelo G. Kazanietz , Protein Kinase C Isozymes, Novel Phorbol Ester Receptors and Cancer Chemotherapy, Current Pharmaceutical Design 2001; 7 (17) . https://dx.doi.org/10.2174/1381612013397041
DOI https://dx.doi.org/10.2174/1381612013397041 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Bioevaluation of Quaternary Centered 3-hydroxy-3 (alkynyl)indolin-2-one Derivatives as Potential Cytotoxic Agents and Akt Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Theoretical Modeling of HPV: QSAR and Novodesign with Fragment Approach
Current Computer-Aided Drug Design Applications of Molecular Imaging in Cancer Gene Therapy
Current Gene Therapy Curcuminoid Metabolism and its Contribution to the Pharmacological Effects
Current Drug Metabolism A Review on the Techniques for Characterizing and Predicting Human Genomic DNA Methylation
Current Bioinformatics Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review
Current Topics in Medicinal Chemistry Modeling and Proposed Molecular Mechanism of Hydroxyurea Through Docking and Molecular Dynamic Simulation to Curtail the Action of Ribonucleotide Reductase
Recent Patents on Anti-Cancer Drug Discovery pH Gradient Reversal: An Emerging Hallmark of Cancers
Recent Patents on Anti-Cancer Drug Discovery Identification of Novel Drug Targets for Angiostatic Cancer Therapy; It Takes Two to Tango
Current Pharmaceutical Design Isolation of Antibodies From Non-Human Primates for Clinical Use
Current Drug Discovery Technologies Prostate Cancer Gene Expression Marker 1 (PCGEM1): A Patented Prostate- Specific Non-Coding Gene and Regulator of Prostate Cancer Progression
Recent Patents on DNA & Gene Sequences Using NMR to Develop New Allosteric and Allo-Network Drugs
Current Drug Discovery Technologies Current Progresses of Functional Nanomaterials for Imaging Diagnosis and Treatment of Melanoma
Current Topics in Medicinal Chemistry Metalloprotein Inhibitors for the Treatment of Human Diseases
Current Topics in Medicinal Chemistry Comprehensive Quality Management (CQM) in the PLCO Trial
Reviews on Recent Clinical Trials Challenges for Drug Discovery - A Case Study of Urokinase Receptor Inhibition
Combinatorial Chemistry & High Throughput Screening Barminomycin, a Model for the Development of New Anthracyclines
Anti-Cancer Agents in Medicinal Chemistry Somatostatin Receptor-Targeted Anti-Cancer Therapy
Current Drug Delivery Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors
Current Cancer Drug Targets Role of MicroRNA 21 in Mesenchymal Stem Cell (MSC) Differentiation: A Powerful Biomarker in MSCs Derived Cells
Current Pharmaceutical Biotechnology